Serving the Society Since 1986
Advanced Search
Volume 39 Issue 5
October 2024
    Citation: Lu Zhang, Siyu Tian, Jun Dai, Yuanyuan Li, Yu Zhou, Yan Li, Jiao Xu, Shuyun Liu, Zhiwei Lin, Zhaoyong Zhang, Jiantao Chen, Peilan Wei, Jingxian Zhao, Jing Jin, Yanqun Wang, Jincun Zhao. Trivalent SARS-CoV-2 virus-like particle vaccines exhibit broad-spectrum neutralization and protection against XBB.1 and BA.2.86 variants .VIROLOGICA SINICA, 2024, 39(5) : 836-839.  http://dx.doi.org/10.1016/j.virs.2024.08.005
    shu

    Trivalent SARS-CoV-2 virus-like particle vaccines exhibit broad-spectrum neutralization and protection against XBB.1 and BA.2.86 variants

    cstr: 32224.14.j.virs.2024.08.005

    • a. State Key Laboratory of Respiratory Disease, Public Health Safety Center Laboratory of General Administration of Customs, Guangzhou Customs Technology Center, Guangzhou, Guangdong, 510182, China;

    • b. Patronus Biotech Co. Ltd., Guangzhou, 510182, China;

    • c. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510182, China;

    • d. Guangzhou National Laboratory, Guangzhou, Guangdong, 510182, China;

    • e. Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510182, China;

    • f. Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China;

    • g. Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital;The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China

    • Highlights
      1. RBDs of the WT, BQ.1.1 and XBB.1 variants were genetically fused and displayed on the VLP to create RBDV14 ​M.
      2. RBDV14 ​M can induce superior antibody responses against the newly emerged SARS-CoV-2 variants XBB.1, EG.5 and BA.2.86.
      3. RBDV14 ​M is one of the few existing next-generation vaccine candidates that utilize virus-like particle platform.
    • 加载中

    • Electronic Supplementary Material

      10.1016j.virs.2024.08.005-ESM.docx

      1. Faraone, J. N., Qu, P., Goodarzi, N., Zheng, Y. M., Carlin, C., Saif, L. J., Oltz, E. M., Xu, K., Jones, D., Gumina, R. J. et al., 2023. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3. Emerg. Microb. Infect.12, 2270069.

      2. Hu, Y., Zou, J., Kurhade, C., Deng, X., Chang, H. C., Kim, D. K., Shi, P. Y., Ren, P., Xie, X., 2023. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1. Emerg. Microb. Infect. 12, 2271089.

      3. Lasrado, N., Collier, A. Y., Hachmann, N. P., Miller, J., Rowe, M., Schonberg, E. D., Rodrigues, S. L., LaPiana, A., Patio, R. C., Anand, T. et al., 2023. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine. 41, 6904-6909.

      4. Li, Y., Zhang, Y., Zhou, Y., Li, Y., Xu, J., Ai, Y., Xu, L., Xiao, X., Zhang, B., Jin, J., 2023. An RBD virus-like particle vaccine for SARS-CoV-2 induces cross-variant antibody responses in mice and macaques. Signal Transduct. Targeted Ther. 8, 173.

      5. Tamura, T., Ito, J., Uriu, K., Zahradnik, J., Kida, I., Anraku, Y., Nasser, H., Shofa, M., Oda, Y., Lytras, S. et al., 2023. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat. Commun. 14, 2800.

      6. Tan, C. W., Chia, W. N., Young, B. E., Zhu, F., Lim, B. L., Sia, W.R., Thein, T. L., Chen, M. I., Leo, Y. S., Lye, D. C. et al., 2021. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N. Engl. J. Med. 385, 1401-1406.

      7. Wang, Q., Guo, Y., Zhang, R. M., Ho, J., Mohri, H., Valdez, R., Manthei, D. M., Gordon, A., Liu, L., Ho, D. D., 2023a. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect. Dis. 23, e397-e398.

      8. Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J. et al., 2023b. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 186, 279-286.

      9. Wang, Q., Guo, Y., Liu, L., Schwanz, L. T., Li, Z., Nair, M. S., Ho, J., Zhang, R. M., Iketani, S., Yu, J. et al., 2023c. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 624, 639-644.

      10. Ward, B. J., Gobeil, P., Seguin, A., Atkins, J., Boulay, I., Charbonneau, P. Y., Couture, M., D'Aoust, M. A., Dhaliwall, J., Finkle, C. et al., 2021. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat. Med. 27, 1071-1078.

      11. Zou, J., Kurhade, C., Patel, S., Kitchin, N., Tompkins, K., Cutler, M., Cooper, D., Yang, Q., Cai, H., Muik, A. et al., 2023. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N. Engl. J. Med. 388, 854-857.

    • 加载中

    Figures(1)

    PDF

    Article Metrics

    Article views(4631) PDF downloads(19) Cited by()

    Related
    Proportional views

      Trivalent SARS-CoV-2 virus-like particle vaccines exhibit broad-spectrum neutralization and protection against XBB.1 and BA.2.86 variants

        Corresponding author: Jingxian Zhao, zhaojincun@gird.cn
        Corresponding author: Jing Jin, jinjing@luye.com
        Corresponding author: Yanqun Wang, wangyanqun@gird.cn
        Corresponding author: Jincun Zhao, zhaojingxian@gird.cn
      • a. State Key Laboratory of Respiratory Disease, Public Health Safety Center Laboratory of General Administration of Customs, Guangzhou Customs Technology Center, Guangzhou, Guangdong, 510182, China;
      • b. Patronus Biotech Co. Ltd., Guangzhou, 510182, China;
      • c. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510182, China;
      • d. Guangzhou National Laboratory, Guangzhou, Guangdong, 510182, China;
      • e. Clinical Laboratory Medicine Department, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510182, China;
      • f. Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China;
      • g. Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital;The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, 518000, China
      • Received Date: 30 March 2024
      • Accepted Date: 13 August 2024

      Abstract: Highlights
      1. RBDs of the WT, BQ.1.1 and XBB.1 variants were genetically fused and displayed on the VLP to create RBDV14 ​M.
      2. RBDV14 ​M can induce superior antibody responses against the newly emerged SARS-CoV-2 variants XBB.1, EG.5 and BA.2.86.
      3. RBDV14 ​M is one of the few existing next-generation vaccine candidates that utilize virus-like particle platform.

        HTML

      Figure (1)  Reference (11) Relative (20)

      目录

      This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return